Баклосан в терапии спастичности / Литература

1. Бурчинский С.Г. Принципы и средства фармакологической коррекции болевых спастических синдромов в неврологии. // Клинический обзор. – Инст. геронтологии АМН Украины. Киев. – 2004. - C.2-4.
2. Воробьева О.В., Козлова И.М. Возможности баклофена в комплексной анальгезии пациентов с острой неспецифической болью в спине. // Cons.-med. – 2006. – Т.08, №8. – С. 48-50.
3. Карнеев А.Н., Соловьева Э.Ю., Федин А.И. Роль препарата баклосан в комплексном лечении болевого синдрома в спине. // Журн. неврол. и психиатр. – 2007. - №5. – С. 15-16.
4. Михеев. В.В. Влияние баклофена на роль левого и правого полушарий головного мозга в регуляции болевой чувствительности и аналгезии у мышей. // Патоогическая боль. – М., 2003. – С.49.
5. Парфенов В.А. Ведение больных со спастичностью. // Русск. мед. журн. – 2004. - Т.12, №10. – 595 С.
6. Albright AL, Ferson SS. Intrathecal baclofen therapy in children. // Neurosurg. Focus. - 2006. – Vol. 21. – P. 3-4.
7. Basmajian JV, Yucel V. Effects of GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study & rehabilitation. // Amer. J. Phys. Med. – 1974. – Vol. 53. – P. 223-224.
8. Basmajian JV. [Lioresal (baclofen) treatment of spasticity in multiple sclerosis]. // Amer. J. Phys. Med. – 1975. – Vol. 54(4). – P. 175-176.
9. Basmajian JV, Shankardass K, Russell D. Ketazolam treatment for spasticity: double-blind study of a new drug. // Arch. Phys. Med. & Rehabil. - 1984. – Vol.65. – P. 698-701.
10. Basmajian JV, Shankardass K, Russell D. Ketazolam once daily for spasticity: double-blind cross-over study. // Arch. Phys. Med. & Rehabil. - 1986. – Vol.67. – P. 556-557.
11. Brar Sp, Smith MB, Nelson LM, Franklin GM, Cobble ND. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. // Arch. Phys. Med. & Rehabil. - 1991. – Vol.72. – P. 186-189.
12. Burke D, Jones RF, Marosszeky JE, Gillies JD. A new agent for the control of spasticity. // J. Neurol. – 1970. – Vol.33. – P. 464-468.
13. Chrzanowski K. A comparative trial of tizanidine and baclofen in the treatment of spasticity due to multiple sclerosis (study no. 26). // Unpublished Sandoz Research Report. - 1981.
14. Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. // Neurology. – 1978. – Vol.28. – P. 1094-1098.
15. Hugenholtz H, Nelson RF, Dehoux E, Bickerton R. Intrathecal baclofen for intractable spinal spasticity-a double blind crossover study in eight patients. // Can. J. Neurol. Sci. – 1992. – Vol.19. – P.188-195.
16. Medaer R., Hellebuyk H., and Van DBE., et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo. // Acta Ther. - 1991. Vol.17. - P. 323-331.
17. Ochiai T, Taira T, Goto S, Hori T. Fifteen year experience of intrathecal baclofen treatment in Japan. // Acta Neurochir Suppl. – 2006. – Vol.99. – P.61-63.
18. Pellkofer M, Paulig M. Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities. // Medizinische Klinik. – 1989. – Vol.84. – P.5-8.
19. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS. Intrathecal baclofen for severe spinal spasticity. // New Engl. J. Med. – 1989. – Vol.320. – P.1517-1521.
20. Reis G.M., Duarte I.D. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. // Br. J. Pharmacol. – 2006. – Vol.149. – P.733-739.
21. Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. // Curr. Med. Res. Opin. – 1981. – Vol.7. – P.374-383.

Комментарии